DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

Information source: Janssen Research & Development, LLC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Participants

Intervention: Abiraterone acetate, 250 mg (uncoated, current commercial tablet) (Drug); Abiraterone acetate, 500 mg (coated, reformulated tablet) (Drug); Abiraterone acetate, 250 mg (coated, reformulated tablet) (Drug); Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution) (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Janssen Research & Development, LLC

Official(s) and/or principal investigator(s):
Janssen Research & Development, LLC Clinical Trial, Study Director, Affiliation: Janssen Research & Development, LLC

Summary

The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication) and relative bioavailability of 3 newly developed abiraterone acetate tablet formulations compared with the current commercial abiraterone acetate tablet formulation in healthy male participants, under fasted conditions, at a single dose of 1000 mg.

Clinical Details

Official title: A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Assess the Relative Bioavailability of 3 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Subjects

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Maximum plasma concentration (Cmax) of abiraterone in coated, reformulated tablet compared to abiraterone in uncoated, current commercial tablet

Area under the plasma concentration versus time curve (AUC) of abiraterone in coated, reformulated tablet compared to abiraterone in uncoated, current commercial tablet

Secondary outcome: Number of participants with adverse events

Detailed description: This is an open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), single-center, 4-way crossover study (method used to switch participants from one treatment arm to another in a clinical trial) of a single dose of abiraterone acetate (1000 mg). The study will consist of 3 phases including screening phase (of 21 days), an open-label treatment phase consisting of 4 single-dose treatment periods, and follow-up phase. All participants will be randomly assigned to 1 of 4 possible treatment sequences to ensure that they receive all of the following treatments, one in each period. The 4 sequences are as follows: Sequence 1: Treatment A, D, B, and C; Sequence 2: Treatment B, A, C, and D; Sequence 3: Treatment C, B, D, and A; and Sequence 4: Treatment D, C, A, and B. After a washout period of 7 days, follow-up phase will occur between 5 to 7 days after the last study procedure. The duration of participation in the study for each participant is from 47 days to a maximum of 68 days (including screening). Pharmacokinetics will be measured by collection of blood samples. Participants will be confined to the study center until completion of the 96 hour pharmacokinetic assessments on Day 5 of each treatment period. Safety evaluations for adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examinations will be monitored throughout the study.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Have body weight not less than 50 kg

- Must be a non-smoker, and has no history of smoking or use of nicotine-containing

substances within the previous 2 months

- Must have blood pressure between 90 and 140 mmHg systolic, inclusive, and no higher

than 90 mmHg diastolic

- Must have a 12-lead electrocardiogram consistent with normal cardiac conduction and

function

- Must agree to use an adequate contraception method as deemed appropriate by the

investigator and to not donate sperm during the study for 3 months after receiving the last dose of study medication Exclusion Criteria:

- History of or current clinically significant medical illness including cardiac

arrhythmias or other cardiac disease that could interfere with the interpretation of the study results

- Clinically significant abnormal values for hematology or urinalysis (at screening)

- Clinically significant abnormal physical examination vital signs or 12-lead

electrocardiogram (at screening)

- Usage of any prescription or nonprescription medication, except for acetaminophen,

and oral contraceptives and hormonal replacement therapy within 14 days before the first dose of the study medication is scheduled

- Unable to swallow solid, oral dosage forms whole with the aid of water (participants

may not chew, divide, dissolve, or crush the study medication)

Locations and Contacts

Tempe, Arizona, United States
Additional Information

Starting date: May 2012
Last updated: March 1, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017